Udhayvir Grewal: Does PD-L1 CPS Matter?
Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport, shared on X: about a recent paper by David H. Ilson published on JCO:
“Thoroughly enjoyed reading this editorial by Dr. Ilson in JCO
KEYNOTE-585: Pembro + cisplatin/5FU ↑ pCR but EFS/OS.
MATTERHORN: Durva + FLOT ↑ pCR and EFS, setting a new periop standard in resectable gastric/GEJ cancer.
Comparable outcomes for FLOT plus pembrolizumab from KEYNOTE-585 and FLOT plus durvalumab from MATTERHORN
Even as a ‘negative’ trial, KEYNOTE-585 reinforces the MATTERHORN results; IO has a role, but the chemo backbone matters.
Big question- does PD-L1 CPS matter?”
Title: KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?
Nina Niu Sanford, Associate Professor at UT Southwestern Medical Center, shared Udhayvir Grewal’s on X:
“It never made sense to me for a Ph3 RCT to have 4 primary endpts: pCR, EFS, OS, safety.
Wo multiplicity strategy (for endpts/looks), KN585 likely pos.
IMO also illustrates challenges in evaluating clinical v stat significance, and again questions why we hang everything on p=0.05.
Btw this was nicely discussed in post by Amol Akhade”
More posts featuring Udhayvir Grewal.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023